Bone News and Research

RSS

Scientists mimic dyskeratosis congenita through study of undifferentiated iPS cells

A rare genetic disease called dyskeratosis congenita, caused by the rapid shortening of telomeres, can be mimicked through the study of undifferentiated induced pluripotent stem cells, according to new findings from the Stanford University School of Medicine.

24 May 2011

3M, Radius collaborate to develop BA058 for treatment of osteoporosis

Radius Health, Inc. and 3M Drug Delivery Systems today announced an agreement to collaborate on the development of a transdermal delivery option of BA058, Radius' novel, proprietary PTHrP analog, for the treatment of osteoporosis.

24 May 2011

Inotuzumab ozogamicin achieves over 50% response rate against acute lymphoblastic leukemia

An antibody packaged with a potent chemotherapy drug to selectively destroy acute lymphoblastic leukemia (ALL) cells eradicated or greatly reduced the disease for 61 percent of 46 patients in a phase II study. It will be presented at the 47th annual meeting of the American Society of Clinical Oncology in Chicago June 3-7.

24 May 2011

Mount Sinai researchers identify protein signaling hyperactivity in human sarcoma cells

Researchers from Mount Sinai School of Medicine have discovered a protein signaling pathway that becomes hyperactivated in human sarcoma cells, suggesting that medications to inhibit this pathway may be effective in the treatment of human sarcomas. The research is published in the current issue of the journal Cancer Cell.

24 May 2011

Journal of Clinical Oncology publishes Exelixis' cabozantinib phase 1 trial results in lymphoma

Exelixis, Inc. today announced the results of the phase 1 clinical trial of cabozantinib in patients with advanced solid tumors or lymphoma have been published in the current issue of the Journal of Clinical Oncology.

24 May 2011

Key U.S. patents increase commercial rights and clinical indications

Australian regenerative medicine company, Mesoblast Limited (ASX:MSB; OTC ADR: MBLTY), today announced that the company’s product development strategy has been significantly strengthened by novel composition of matter claims granted by the United States Patent and Trade Mark Office (USPTO) in two distinct patent families to which Mesoblast has exclusive worldwide commercial rights.

23 May 2011

New genetic testing technology for IVG embryos

Researchers at the Johns Hopkins University School of Medicine have devised a new technique, which helps couples that are affected by or are carriers of genetic diseases have in vitro fertilized babies free of both the disease in question and other chromosomal abnormalities. The results were reported in the April issue of Fertility and Sterility.

23 May 2011

PolyPid announces new drug delivery system and an innovative biodegradable bone void filler

PolyPid, a developer of innovative drug carriers, announced today the company’s flagship platform – PolyPid. PolyPid is a new, innovative family of drug carriers, based on a fusion between two known drug delivery systems: polymers and lipid-based systems. The new drug carriers enable long-lasting and controlled release of therapeutic drugs. The revolutionary, patented carrier can be tailored to almost any drug – small molecules, peptides, protein and nucleic acids-based drugs. The formulations can be pre-planned in order to achieve the desired release rate of the drug/s and the optimal duration, which can last up to several months.

23 May 2011

Automated microfluidic device can monitor hematopoietic stem cells

A Canadian research team has developed an automated microfluidic cell culture platform to monitor the growth, survival and responses of hundreds of hematopoietic stem cells at the single cell level.

23 May 2011

New insights into bone diseases

A study by researchers at Children's Hospital Boston and collaborators at other institutions has provided new insights into the means by which bone cells produce new bone in response to mechanical stresses, such as exercise.

23 May 2011

Modified cells protect marrow and blood cells from harmful chemotherapy effects in brain tumor patients

Although chemotherapy is used to kill cancer cells, it can also have a strong toxic effect on normal cells such as bone marrow and blood cells, often limiting the ability to use and manage the chemotherapy treatment.

21 May 2011

Stony Brook University CFB establishes Biotechnology Commercialization Fund

The Center for Biotechnology (CFB) at Stony Brook University has established the Biotechnology Commercialization Fund to accelerate the development of promising biomedical technologies emerging from Stony Brook University.

21 May 2011

High heels and narrow toe boxes lead to toe deformities in women

According to a recent study, 39 percent of women say they wear high heels every day, and 75 percent of those women say they experience regular shoe-related foot pain and suffer from bunions, arthritic big toes, calluses, hammer toes, and plantar warts.

21 May 2011

Artificial discs a viable alternative to fusion surgery for two-level lumbar degenerative disc disease

When two adjacent discs in the low back wear out, become compressed and cause unmanageable pain, numbness or other symptoms, replacement with artificial discs can be a viable alternative to standard fusion surgery, based on two-year post-surgery data from a randomized, multicenter trial recently published in the Journal of Bone and Joint Surgery.

21 May 2011

Study examines long-term GI complications in childhood cancer survivors

Individuals who are treated for cancer during childhood have a significantly higher risk of developing gastrointestinal complications - from mild to severe - later in life, according to a study led by the University of California, San Francisco. The findings underscore the need for childhood cancer survivors and their physicians to be aware of these risk factors to ensure patients' ongoing health care needs are met.

21 May 2011

EMA CHMP recommends positive opinion for marketing authorization of Amgen's XGEVA

Amgen today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended a positive opinion for the marketing authorization of XGEVA (denosumab) for the prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumors.

20 May 2011

Merck's VICTRELIS receives European CHMP positive opinion for treatment of chronic HCV genotype 1 infection

Merck, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion under accelerated assessment recommending approval of the investigational medicine VICTRELIS (boceprevir) for the treatment of chronic hepatitis C virus genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy.

20 May 2011

International team identifies key protein in development of drug-resistant leukemia

Now an international team led by researchers at the University of California, San Francisco and joined by scientists of the Freiburg excellence cluster BIOSS - Centre for Biological Signalling Studies, has identified a protein called BCL6 which plays a key role in the development of drug-resistance in leukemia.

20 May 2011

Osteoarthritis directly linked to low-fat, high-carb food

Osteoarthritis is a degenerative joint disease and the most common cause of disability today. It was once considered a problem of the old but it is now commonly diagnosed in those as young as the mid-twenties and early thirties. According to the Arthritis Foundation, about four million, quality-adjusted life years are lost due to knee osteoarthritis alone.

20 May 2011

Tornier announces launch of Porous Coated Affiniti Stem for shoulder joint replacement surgery

Tornier Inc. the operating subsidiary of Tornier N.V., a leading global medical device company focused on serving extremities specialists who treat orthopedic conditions of the shoulder, elbow, wrist, hand, ankle and foot, today announced the introduction of the Porous Coated Affiniti Stem for shoulder joint replacement surgery.

20 May 2011

Bone News and Research

Scientists mimic dyskeratosis congenita through study of undifferentiated iPS cells

3M, Radius collaborate to develop BA058 for treatment of osteoporosis

Inotuzumab ozogamicin achieves over 50% response rate against acute lymphoblastic leukemia

Mount Sinai researchers identify protein signaling hyperactivity in human sarcoma cells

Journal of Clinical Oncology publishes Exelixis' cabozantinib phase 1 trial results in lymphoma

Key U.S. patents increase commercial rights and clinical indications

New genetic testing technology for IVG embryos

PolyPid announces new drug delivery system and an innovative biodegradable bone void filler

Automated microfluidic device can monitor hematopoietic stem cells

New insights into bone diseases

Modified cells protect marrow and blood cells from harmful chemotherapy effects in brain tumor patients

Stony Brook University CFB establishes Biotechnology Commercialization Fund

High heels and narrow toe boxes lead to toe deformities in women

Artificial discs a viable alternative to fusion surgery for two-level lumbar degenerative disc disease

Study examines long-term GI complications in childhood cancer survivors

EMA CHMP recommends positive opinion for marketing authorization of Amgen's XGEVA

Merck's VICTRELIS receives European CHMP positive opinion for treatment of chronic HCV genotype 1 infection

International team identifies key protein in development of drug-resistant leukemia

Osteoarthritis directly linked to low-fat, high-carb food

Tornier announces launch of Porous Coated Affiniti Stem for shoulder joint replacement surgery

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News